Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyDiseaseHepatocellular CarcinomaSubgroupICD10C22.0MeSHCarcinoma, HepatocellularLiver DiseasesLiver NeoplasmsSequenceCheckMate 040: NIVO1/IPIL3, HCC (PID1788) -|- NIVO240, maint. (PID1789)HIMALAYA: TREM300/DURV1500, HCC, C1 (PID2288) -|- DURV1500, C2+ (PID2289)ChemotherapyChemo-substanceAtezolizumabBevacizumabCabozantinibDurvalumabFluorouracilFolinic acidIpilimumabLenvatinibNivolumabOxaliplatinPembrolizumabRamucirumabRegorafenibSorafenibTremelimumabChemo-substanceAtezolizumabBevacizumabCabozantinibDurvalumabFluorouracilFolinic acidIpilimumabLenvatinibNivolumabOxaliplatinPembrolizumabRamucirumabRegorafenibSorafenibTremelimumabChemo-substanceAtezolizumabBevacizumabCabozantinibDurvalumabFluorouracilFolinic acidIpilimumabLenvatinibNivolumabOxaliplatinPembrolizumabRamucirumabRegorafenibSorafenibTremelimumabChemo-substanceAtezolizumabBevacizumabCabozantinibDurvalumabFluorouracilFolinic acidIpilimumabLenvatinibNivolumabOxaliplatinPembrolizumabRamucirumabRegorafenibSorafenibTremelimumabNo. Substances124 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneDimetindenGranisetronNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseInductionMaintenanceTherapy intentionpalliativeRisksAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlAstheniaBleedingCardiotoxicityColitisDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueHand-Foot SyndromeHemorrhageHepatotoxicityHyperbilirubinemiaHyperkalemiaHypertensionHyperthyroidismHypophosphatemiaHypophysitisHypothyroidismIncrease AminotransferasesIncrease in lipaseInfusion ReactionMucositisNeutropeniaPancreatitisPneumonitisProteinuriaPruritusPyrexiaRashThrombocytopenia below 50 000/µlThromboembolic Event only studiesPublicationAuthorAbou-Alfa GKBruix JFinn RSKim HDKudo MLlovet JMinKe HeYau TZhu ADiseasefortgeschrittenes Leberzellkarzinom, Erstlinie, ECOG 0-2HCC, nach Therapie mit Sorafenib, Child–Pugh A, ECOG 0-1HCC lokal fortgeschritten oder metastasiert, nicht operabel, BCLC B oder C, ChildPugh A, ECOG 0-1HCC mit Fernmetastasen oder einer Tumorlokalisation, die lokoregionär nicht kontrolliert oder reseziert werden kann, ChildPugh A, ECOG 0-1HCC mit Fernmetastasen oder nicht resektabelHCC nicht operabel, Child-Pugh A, ECOG 0-1, Erstlinientherapiehepatozelluläres Karzinom, portal vein invasion, Child Pugh Class A, Erstlinie, ECOG 0-2hepatozelluläres Karzinom, Zweitlinie nach Sorafenib, Child-Pugh-Class A, ECOG 0-1Leberzellkarzinom, Zweitlinie nach Sorafenib, Child-Pugh A, ECOG 0-1nichtresezierbares hepatozelluläres Karzinom, Erstlinie, ECOG 0-1OriginBarcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, SpainDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, JapanGeffen School of Medicine at UCLA, Santa Monica, USA, IMbrave150Keynote 224Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, REACH-2Memorial Sloan Kettering Cancer Center, New York, HIMALAYA trialMemorial Sloan Kettering Cancer Center, New York, USA, CELESTIAL trialSHARP investigator´s studySun Yatsen University Cancer Center, State KeyLaboratory of Oncology in SouthChinaUniversity of Hong Kong, China, CheckMate 040University of Ulsan College of Medicine, Seoul, Republic of Korea, RENOBATE trialProtocols in Revision 14 protocols foundProtocols under revision.Atezolizumab 1200 / Bevacizumab 15, Hepatocellular Carcinoma (PID1537 V1.0)Cabozantinib 60, Hepatocellular Carcinoma (PID1558 V1.1)Durvalumab 1500, Hepatocellular Carcinoma (PID2510 V1.0)Lenvatinib 12, Hepatocellular Carcinoma (PID79 V1.0)Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Hepatocellular Carcinoma, Maintenance (PID1789 V1.1)Nivolumab 1 / Ipilimumab 3, Hepatocellular Carcinoma (PID1788 V1.2)Nivolumab 480 / Regorafenib 80, Hepatocellular Carcinoma (PID2572 V1.0)Pembrolizumab 200, Hepatocellular Carcinoma (PID1376 V1.0)Ramucirumab 8, Hepatocellular Carcinoma (PID1400 V1.0)Regorafenib 160, hepatocellular carcinoma (PID248 V1.0)Sorafenib 400 / Oxaliplatin 85 / Folinic Acid 400 / Fluorouracil 2400, Hepatocellular Carcinoma (PID675 V1.0)Sorafenib 400, hepatocellular carcinoma (PID749 V1.1)Tremelimumab 300 / Durvalumab 1500 - Durvalumab 1500, Hepatocellular Carcinoma, Cycle 2+ (PID2289 V1.0)Tremelimumab 300 / Durvalumab 1500, Hepatocellular Carcinoma, Cycle 1 (PID2288 V1.0)
